INT107376

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 4.39
Pain Relevance 1.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (P2ry12) plasma membrane (P2ry12) signal transducer activity (P2ry12)
Anatomy Link Frequency
platelet 8
brain 1
P2ry12 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
adenocard 22 100.00 Very High Very High Very High
antagonist 17 100.00 Very High Very High Very High
cINOD 6 99.72 Very High Very High Very High
aspirin 61 98.98 Very High Very High Very High
COX-2 inhibitor 5 86.28 High High
withdrawal 1 84.88 Quite High
Angina 19 81.76 Quite High
Inflammatory response 3 75.04 Quite High
Central nervous system 1 73.88 Quite High
Onset of action 2 60.08 Quite High
Disease Link Frequency Relevance Heat
Acute Coronary Syndrome 76 97.96 Very High Very High Very High
Thrombosis 246 96.76 Very High Very High Very High
Diabetes Mellitus 293 96.28 Very High Very High Very High
Emergencies 11 91.64 High High
Myocardial Infarction 61 90.44 High High
Coronary Artery Disease 63 89.48 High High
Hemorrhage 54 82.64 Quite High
Liver Disease 4 81.96 Quite High
Cv General 3 Under Development 20 81.76 Quite High
Cv General 4 Under Development 10 77.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In Norway, different attitudes prevail to discontinuation of antiplatelet agents, such as ASA, NSAID, ADP-receptor inhibitors (clopidogrel and ticlopidine) phosphodiestase inhibitors (dipyridamole) and glycoprotein IIb/IIIa receptor inhibitors (abciximab and eptifibatide), before endoscopic procedures.
Negative_regulation (inhibitors) of ADP-receptor associated with cinod
1) Confidence 0.43 Published 2008 Journal Tidsskr. Nor. Laegeforen. Section Abstract Doc Link 19096466 Disease Relevance 0 Pain Relevance 0.10
They are prodrugs and are metabolised in the liver to active metabolites that are non-competitive antagonists of the platelet adenosine diphosphate receptor, P2Y12.
Negative_regulation (antagonists) of P2Y12 in platelet associated with adenocard and antagonist
2) Confidence 0.26 Published 2003 Journal Anaesthesia Section Abstract Doc Link 12492666 Disease Relevance 0.20 Pain Relevance 0.22
A blood sample was withdrawn 12 hours later, but before PCI, to assess platelet reactivity using the P2Y12 reaction unit and percentage of P2Y12 inhibition with the point-of-care VerifyNow P2Y12 assay.
Negative_regulation (using) of P2Y12 in platelet
3) Confidence 0.23 Published 2010 Journal Am. J. Cardiol. Section Abstract Doc Link 20102944 Disease Relevance 0.29 Pain Relevance 0.22
A blood sample was withdrawn 12 hours later, but before PCI, to assess platelet reactivity using the P2Y12 reaction unit and percentage of P2Y12 inhibition with the point-of-care VerifyNow P2Y12 assay.
Negative_regulation (inhibition) of P2Y12 in platelet
4) Confidence 0.21 Published 2010 Journal Am. J. Cardiol. Section Abstract Doc Link 20102944 Disease Relevance 0.29 Pain Relevance 0.22
Third generation tienopyridine prasugrel provides faster onset and greater inhibition of P2Y12 receptor-mediated platelet aggregation than clopidogrel, because of greater and more efficient generation of the active metabolite [15,16].
Negative_regulation (inhibition) of P2Y12 in platelet
5) Confidence 0.19 Published 2009 Journal Thromb J Section Body Doc Link PMC2693432 Disease Relevance 0.35 Pain Relevance 0.03
The phosphorylation status of VASP correlates with P2Y12 receptor inhibition, whereas its non-phosphorylation state correlates with the active form of the P2Y12 receptor.
Negative_regulation (inhibition) of P2Y12
6) Confidence 0.19 Published 2009 Journal Thromb J Section Body Doc Link PMC2693432 Disease Relevance 0.52 Pain Relevance 0.09
Flow cytometric determination of VASP phosphorylation state strongly correlated with the inhibition of ADP-induced platelet aggregation resulting from specific P2Y12 blockade by a specific antagonist of the P2Y12 receptor (AR-C69931MX) [6].
Negative_regulation (blockade) of P2Y12 in platelet associated with antagonist
7) Confidence 0.17 Published 2009 Journal Thromb J Section Body Doc Link PMC2693432 Disease Relevance 0.34 Pain Relevance 0.09
The present study adds further dimensions to this scheme by demonstrating that RSNOs can inhibit platelet (and brain) P2Y12 receptor function via cGMP-independent mechanisms, likely involving S-nitrosylation.
Negative_regulation (inhibit) of P2Y12 in brain
8) Confidence 0.16 Published 2005 Journal BMC Cell Biol Section Body Doc Link PMC1090567 Disease Relevance 0 Pain Relevance 0.04
The current standard of care for ACS patients is dual antiplatelet therapy with aspirin and clopidogrel, although studies show that newer P2Y12 inhibitors, including prasugrel and ticagrelor, are more effective than clopidogrel.26,27 Limitations of clopidogrel include relatively slow onset of effect, low PAI in many patients, inter-individual variability in response, and irreversible P2Y12 binding that prevents rapid offset of effect.
Negative_regulation (inhibitors) of P2Y12 associated with aspirin and acute coronary syndrome
9) Confidence 0.13 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2966970 Disease Relevance 0.71 Pain Relevance 0.11
The study showed that cilostazol compared with placebo was associated with marked inhibition of P2Y12 signaling.105 Current guidelines specify a class IIb indication with a level of evidence C that the dose of clopidogrel can be increased to 150 mg per day if <50% inhibition of platelet aggregation is demonstrated only in patients in whom stent thrombosis may be catastrophic or lethal (such as unprotected left main, bifurcating left main and last patent coronary vessel).106 However, although the use of a 150-mg maintenance dose of clopidogrel in patients with type 2 DM and with <50% platelet inhibition has been shown to be associated with enhanced antiplatelet effects, these effects are nonuniform and many patients persist with inadequate platelet inhibition.107 Probably the use of more potent P2Y12 inhibitors, with their uniform and potent effect, could help us resolve this problem.
Negative_regulation (inhibition) of P2Y12 in platelet associated with diabetes mellitus and thrombosis
10) Confidence 0.06 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672443 Disease Relevance 0.63 Pain Relevance 0
Clopidogrel has a potent anti-thrombotic action by blocking P2Y12, a platelet ADP receptor, and also inhibits platelet aggregation induced by collagen.15)23)
Negative_regulation (blocking) of P2Y12 in platelet
11) Confidence 0.06 Published 2010 Journal Korean Circulation Journal Section Body Doc Link PMC2910288 Disease Relevance 0.49 Pain Relevance 0.36
Prasugrel is a third-generation P2Y12 inhibitor, with more potent and less variable antiplatelet effects compared with clopidogrel.108,109 Recently, the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction) trial showed significantly reduced rates of ischemic events, including stent thrombosis, in patients presenting with acute coronary syndromes undergoing PCI treated with prasugrel compared with clopidogrel.110 The net clinical benefit achieved with prasugrel in the general study population still has statistical significance for better clinical outcomes although diminished by an increased risk of bleeding.
Negative_regulation (inhibitor) of P2Y12 in Platelet associated with acute coronary syndrome, hemorrhage, thrombosis and myocardial infarction
12) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672443 Disease Relevance 0.56 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox